Both bitcoin and U.S. stock futures shot up on Monday after a U.S. pharmaceutical giant announced positive results from a large-scale clinical trial of a coronavirus vaccine.
Risk appetite improved as Pfizer said its experimental vaccine has been 90% effective in preventing infections in the ongoing trial, Bloomberg reported. The news raises hopes that there may soon be an effective treatment for COVID-19, which is again running rampant through regions such as the U.S. and Europe.
Gold, meanwhile, fell from $1,950 to $1,900 as investors sold safe-haven assets amid the rally on Wall Street.
The coronavirus pandemic brought the global economy to a near standstill in the second quarter and its recent resurgence is threatening to derail the fragile economic recovery. The vaccine news, therefore, bodes well for growth-sensitive stocks and other risky assets.
While the S&P 500 futures continue to trade near record highs, bitcoin has erased gains to trade near $10,500.
The cryptocurrency's rally from October lows below $10,500 has stalled below $16,000 over the past couple of days. But on Sunday, a weekly close above last year's high opened the door for a continued rally toward bitcoin's $20,000 price record.
The leader in news and information on cryptocurrency, digital assets and the future of money, CoinDesk is a media outlet that strives for the highest journalistic standards and abides by a strict set of editorial policies. CoinDesk is an independent operating subsidiary of Digital Currency Group, which invests in cryptocurrencies and blockchain startups. As part of their compensation, certain CoinDesk employees, including editorial employees, may receive exposure to DCG equity in the form of stock appreciation rights, which vest over a multi-year period. CoinDesk journalists are not allowed to purchase stock outright in DCG.